Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Other Non-Current Liabilities (2020 - 2025)

UroGen Pharma's Other Non-Current Liabilities history spans 6 years, with the latest figure at $3.9 million for Q4 2025.

  • For Q4 2025, Other Non-Current Liabilities rose 2.95% year-over-year to $3.9 million; the TTM value through Dec 2025 reached $3.9 million, up 2.95%, while the annual FY2025 figure was $3.9 million, 2.95% up from the prior year.
  • Other Non-Current Liabilities reached $3.9 million in Q4 2025 per URGN's latest filing, up from $3.8 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $3.9 million in Q4 2025 to a low of $2.7 million in Q1 2021.
  • Average Other Non-Current Liabilities over 5 years is $3.2 million, with a median of $3.0 million recorded in 2022.
  • Peak YoY movement for Other Non-Current Liabilities: grew 18.69% in 2024, then grew 2.95% in 2025.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $2.8 million in 2021, then increased by 6.19% to $3.0 million in 2022, then grew by 5.83% to $3.2 million in 2023, then increased by 18.69% to $3.8 million in 2024, then grew by 2.95% to $3.9 million in 2025.
  • Per Business Quant, the three most recent readings for URGN's Other Non-Current Liabilities are $3.9 million (Q4 2025), $3.8 million (Q3 2025), and $3.8 million (Q2 2025).